Low-Dose Aspirin Linked to 14% Lower Odds of Synchronous Metastatic Colorectal Cancer in Population Study
Regular low-dose aspirin use is associated with a 14 percent reduction in the odds of presenting with synchronous distant metastatic colorectal cancer, according to a population-based study published in the British Journal of Cancer.
Researchers identified this link by examining data from 81,269 patients diagnosed with colorectal cancer in Sweden between 2008 and 2021,, using the Colorectal Cancer Database Sweden (CRCBaSe) to track clinical outcomes against prescription records.
- Patients currently taking prescribed low-dose aspirin showed a 14 percent lower likelihood of having metastatic disease at the time of their initial cancer diagnosis.
- The protective association was notably stronger in right-sided colon tumors, where current aspirin use correlated with a 21 percent reduction in metastatic risk.
- The study utilized nationwide Swedish health registers to track medication history, ensuring that over-the-counter acquisition did not confound the analysis of prescribed low-dose regimens.
The investigation into the role of acetylsalicylic acid in oncological outcomes follows a long history of research into its potential chemopreventive effects. While earlier studies—including rodent models from 1972 and human epidemiological findings from 1988—suggested that aspirin might inhibit cancer progression, results from randomized clinical trials have remained inconsistent.
The current analysis, published in the British Journal of Cancer, aimed to clarify these associations by analyzing a large, unselected population rather than a controlled trial cohort.
Researchers defined current aspirin users as those who had dispensed at least 365 pills of low-dose aspirin within two years of their cancer diagnosis. By linking the Swedish Colorectal Cancer Registry with the Swedish Prescribed Drug Register, the study team accounted for potential confounders such as age, sex, socioeconomic status, and preexisting comorbidities like cardiovascular disease and diabetes.
The data suggests that the benefit is not limited to active users, as past aspirin users also demonstrated reduced metastatic odds for right-sided lesions.

The study highlights a distinct difference in how aspirin interacts with tumors based on their location within the bowel. The 21 percent reduction in metastatic risk observed in right-sided colon tumors did not consistently extend to left-sided malignancies. This anatomical variation suggests that the biological pathways influenced by aspirin may differ across the colorectal tract, a finding that aligns with emerging research into the molecular heterogeneity of colorectal cancer.
Colorectal cancer remains a major global health burden, with about 20 percent of patients diagnosed at stage IV.
The study was conducted using data from the CRCBaSe, which integrates the Swedish Colorectal Cancer Registry and the National Patient Register. Because low-dose aspirin in Sweden is restricted to medical prescription, the researchers were able to avoid the data gaps often associated with over-the-counter supplement use.
This methodological rigor provides a clearer view of the dose-dependent effects of aspirin, though the researchers said that further investigations are required to determine the optimal duration of therapy for maximizing protective benefits against metastatic spread.
While the reduction in metastatic odds is statistically significant, the study does not suggest that aspirin serves as a replacement for standard screening protocols. Future clinical efforts will likely focus on finding which patient groups benefit most from aspirin-based chemoprevention, as colorectal cancer cases are expected to rise sharply by 2045.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.